IDEXX Laboratories Inc (XTER:IX1)
€ 417.5 0.9 (0.22%) Market Cap: 34.07 Bil Enterprise Value: 34.69 Bil PE Ratio: 44.50 PB Ratio: 23.46 GF Score: 99/100

IDEXX Laboratories Inc at Goldman Sachs Healthcare C-Suite Unscripted Conference Transcript

Jan 04, 2024 / 06:30PM GMT
Release Date Price: €492.8 (+1.17%)
Nathan Allen Rich
Goldman Sachs Group, Inc., Research Division - Research Analyst

All right. Given we're running a few minutes late, let's get started. Thanks for joining us for our next session with IDEXX Labs. They're a leading provider of diagnostic solutions for the animal health industry. Very pleased to have Jay Mazelsky, President and CEO, with us today, and John Ravis from IR in the audience. My name is Nathan Rich, and I cover the animal health space here at Goldman Sachs.

Questions & Answers

Nathan Allen Rich
Goldman Sachs Group, Inc., Research Division - Research Analyst

Maybe to start, Jay, just keeping it high level, could you frame the company's performance in 2023 and then looking forward, kind of what do you see as the state of the industry and kind of strategic priorities for the business in 2024?

Jonathan J. Mazelsky
IDEXX Laboratories, Inc. - President, CEO & Director

Sure. Glad too, Nathan. Thanks for having us. I appreciate it. Yes, I always like -- let me just first start off

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot